What is the comprehensive management approach for a patient with chronic coronary syndrome?

Comprehensive Management of Chronic Coronary Syndrome

Initial Risk Stratification and Diagnosis

All patients with chronic coronary syndrome require systematic risk stratification using stress imaging or invasive coronary angiography with functional assessment (FFR/iFR) to guide treatment intensity and revascularization decisions. 1, 2

High-Risk Features Requiring Invasive Evaluation

Proceed directly to invasive coronary angiography with FFR/iFR in patients with: 1, 2

• Duke Treadmill Score < −10
• ≥10% LV myocardium with ischemia on SPECT/PET
• ≥3 of 16 segments with stress-induced wall motion abnormalities on echocardiography
• ≥2 of 16 segments with stress perfusion defects on CMR
• Left main disease ≥50% stenosis, three-vessel disease ≥70%, two-vessel disease ≥70% including proximal LAD, or isolated proximal LAD ≥70% with FFR-CT ≤0.8 on CCTA

Baseline Assessment

Obtain resting echocardiography in all patients to quantify left ventricular function, as this directly impacts prognosis and treatment selection. 3

---

Lifestyle Modifications (Foundation of All Treatment)

Implement a multidisciplinary exercise-based cardiac rehabilitation program as this reduces cardiovascular mortality independent of pharmacological therapy. 1, 4, 2

Specific Exercise Prescription

• Aerobic activity: 150-300 minutes per week of moderate intensity OR 75-150 minutes per week of vigorous intensity 1, 2
• Actively reduce sedentary time throughout the day 1
• Utilize mobile health interventions (text messages, apps, wearable devices) to improve adherence 2

Multidisciplinary Team Involvement

Engage cardiologists, primary care physicians, nurses, dieticians, physiotherapists, psychologists, and pharmacists in coordinated care. 4, 2, 3 Provide psychological interventions specifically for patients with depressive symptoms. 4

Vaccination

Administer annual influenza vaccination, particularly in elderly patients, as this reduces cardiovascular events. 4, 2, 3

---

Pharmacological Management for Symptom Relief

Initiate beta-blockers and/or calcium channel blockers as first-line therapy for heart rate control and symptom management in most patients. 1, 4, 2

Immediate Symptom Relief

• Short-acting nitrates for immediate relief of angina episodes 1, 4, 2, 3
• Critical contraindication: Never use nitrates in patients with hypertrophic cardiomyopathy or when co-administered with phosphodiesterase inhibitors 1, 4, 2

First-Line Antianginal Therapy

Select based on patient-specific factors: 1, 4, 2

Beta-blockers (e.g., metoprolol):

• Particularly beneficial in patients with prior MI or heart failure 4
• In diabetes, prefer vasodilating beta-blockers to avoid adverse metabolic effects 3
• Caution: Monitor for bradycardia, heart block, and cardiac arrest; reduce or stop if severe bradycardia develops 5
• Caution: May mask hypoglycemia symptoms (tachycardia) in diabetic patients, though dizziness and sweating remain 5
• Elimination half-life 3-4 hours (7-9 hours in poor CYP2D6 metabolizers) 5

Calcium channel blockers:

• Alternative or combination option with beta-blockers 1, 4, 2

Drugs to Avoid

• Do NOT use ivabradine as add-on therapy in patients with LVEF >40% and no clinical heart failure 1
• Do NOT combine ivabradine with non-dihydropyridine CCBs or strong CYP3A4 inhibitors 1, 2

---

Pharmacological Management for Event Prevention

Lipid-Lowering Therapy (Universal Recommendation)

All patients with chronic coronary syndrome require statin therapy regardless of baseline LDL-C levels. 4, 2, 3

Stepwise intensification algorithm: 4, 2, 3

1. Step 1: Initiate high-intensity statin
2. Step 2: If LDL-C goals not achieved on maximum tolerated statin dose, add ezetimibe
3. Step 3: For very high-risk patients not achieving goals on statin + ezetimibe, add PCSK9 inhibitor

Antithrombotic Therapy

The default strategy is aspirin 75-100 mg daily lifelong after an initial period of dual antiplatelet therapy (DAPT) in patients with prior MI or revascularization. 1, 4, 2, 3

Post-PCI Antithrombotic Strategy

Standard approach: 1, 4, 3

• Aspirin 75-100 mg daily + clopidogrel 75 mg daily for 6 months after PCI-stenting (default duration)
• Then transition to aspirin 75-100 mg daily alone lifelong

High bleeding risk modification: 1, 2

• Discontinue DAPT at 1-3 months post-PCI if patient is NOT at high ischemic risk
• Continue single antiplatelet therapy thereafter

Alternative to Aspirin

Clopidogrel 75 mg daily is a safe and effective alternative to aspirin monotherapy in patients with aspirin intolerance. 1, 4, 2, 3

Post-CABG

Aspirin 75-100 mg daily lifelong 1

Patients Without Prior MI or Revascularization

Aspirin 75-100 mg daily lifelong if significant obstructive CAD is documented 1

Concomitant Oral Anticoagulation (e.g., Atrial Fibrillation)

In patients requiring long-term oral anticoagulation: 1, 2

• Preferred: Direct oral anticoagulant (DOAC) over vitamin K antagonist (VKA) 1
• After uncomplicated PCI: Early cessation of aspirin (≤1 week), then continue OAC + clopidogrel up to 6 months 1
• During initial PCI: Add low-dose aspirin once daily to OAC + clopidogrel 1

Gastroprotection

Use concomitant proton pump inhibitor in patients at high risk of gastrointestinal bleeding. 4

ACE Inhibitors or ARBs

Indicated in patients with: 4, 2

• Heart failure
• Hypertension
• Diabetes mellitus

Diuretics

Use in symptomatic patients with signs of pulmonary or systemic congestion. 4

---

Revascularization Strategy

Invasive coronary angiography with functional assessment (FFR/iFR) is indicated for symptomatic patients with high-risk clinical profiles, particularly when symptoms respond inadequately to medical treatment. 1, 4, 2, 3

Indications for Invasive Evaluation

• Symptoms refractory to optimal medical therapy 1, 2
• High-risk features on non-invasive testing (see criteria above) 1, 2
• Deteriorating left ventricular function 2

Critical Principle

Invasive functional assessment (FFR/iFR) must be available and used to evaluate stenoses before revascularization, unless stenosis is very high grade (>90% diameter stenosis). 3 This refines risk stratification and improves outcomes by ensuring appropriate revascularization decisions. 1

---

Follow-Up and Monitoring

Review patient response to medical therapies within 2-4 weeks after drug initiation to ensure efficacy and tolerability. 4, 2, 3

Ongoing Surveillance

• Annual visits to healthcare professional to evaluate risk factor control and assess disease status changes 2
• Reassess CAD status in patients with deteriorating left ventricular function 2
• Simplify medication regimens using fixed-dose combinations to increase adherence 2

Patient Education

Provide comprehensive education about the disease, risk factors, and treatment strategy at every encounter. 4 Emphasize that chronic coronary syndrome is a lifelong condition requiring continuous management. 6, 7

---

Critical Pitfalls to Avoid

Abrupt Beta-Blocker Discontinuation

Never abruptly discontinue beta-blocker therapy in patients with coronary artery disease. 5 Severe exacerbation of angina, MI, and ventricular arrhythmias have been reported. When discontinuing, taper gradually over 1-2 weeks with careful monitoring. 5 If angina worsens markedly, reinstate beta-blocker immediately and manage as unstable angina. 5

Perioperative Management

Do not routinely withdraw chronically administered beta-blockers prior to major surgery, though recognize the impaired ability of the heart to respond to reflex adrenergic stimuli. 5

Bronchospastic Disease

Use beta-blockers cautiously in bronchospastic disease; if necessary, use lowest possible dose of metoprolol in smaller divided doses (three times daily instead of twice daily) to avoid higher peak plasma levels. 5 Ensure bronchodilators including beta-2 agonists are readily available. 5

Pheochromocytoma

If using beta-blockers in pheochromocytoma, always combine with an alpha blocker initiated first, as beta-blockade alone can cause paradoxical hypertension. 5

Thyrotoxicosis

Beta-blockers may mask tachycardia of hyperthyroidism; avoid abrupt withdrawal which might precipitate thyroid storm. 5

Misclassification of Chest Pain

Never classify chest pain as non-cardiac without thorough evaluation including objective exclusion of myocardial ischemia. 2 Recognize that symptom severity does not always correlate with obstructive CAD severity, particularly in women. 2

Coronary Calcification Imaging

Do not use coronary CTA when extensive coronary calcification is present, as good image quality is unlikely. 3 However, if coronary calcification findings are available from previous chest CT scans, incorporate these into risk stratification. 3

---

Special Populations

Older Adults

Base diagnostic and revascularization decisions on symptoms, extent of ischemia, frailty, life expectancy, comorbidities, and patient preferences. 2 Plasma metoprolol concentrations may be slightly higher due to decreased metabolism and hepatic blood flow, though this is not clinically significant. 5

Women

Apply similar guideline-directed cardiovascular preventive therapy as in men. 2 Do NOT use systemic post-menopausal hormone therapy due to lack of cardiovascular benefit and increased thromboembolic risk. 2

Diabetes Mellitus

Patients often have more extensive coronary calcification and complex anatomy. 3 Prefer vasodilating beta-blockers to avoid adverse metabolic effects. 3 Remember that beta-blockers mask hypoglycemia-induced tachycardia but not dizziness or sweating. 5

Renal Impairment

No dosage reduction of metoprolol is usually needed in chronic renal failure, as systemic availability and half-life do not differ clinically from normal subjects. 5

Hepatic Impairment

Metoprolol elimination half-life is considerably prolonged (up to 7.2 hours) depending on severity, as the drug is primarily eliminated by hepatic metabolism. 5

HIV

Pay attention to interactions between antiretroviral treatment and statins. 2

High-Risk Subgroup: Prior MI with Current Angina

Patients with both prior MI and current angina represent an easily identifiable high-risk group with primary event rates of 11.8% at 5 years compared to 8.2% in those without angina. 8 These patients deserve intensive treatment and close monitoring. 8